Mobile App

Google Play Apple Store
Novel Therapeutic Approaches to Pulmonary Arterial Hypertension
Current guidelines recommend initial oral combination therapy for patients with low- or intermediate-risk pulmonary arterial hypertension (PAH) and initial combination therapy including intravenous prostacyclin for high-risk patients. These strategies are based on using regular multiparameter mortality risk assessments and proactive therapy escalation to achieve and maintain a low-risk status. This approach has been shown to slow disease progression, optimize clinical outcomes, and improve survival. Furthermore, as interest towards personalized medicine grows, a comprehensive understanding of patient phenotypes through multiomics approaches, called deep phenotyping, is needed to provide further insights on pathogenesis, diagnosis, prognosis and therapeutic outcomes.

This AMA/ANCC/ACPE accredited, on-demand video addresses some key questions on combination therapy and deep phenotyping featuring a PAH expert answering important commonly asked questions.
Review the activity and claim AMA, ANCC or ACPE credit/contact hour after completion of a brief pretest and posttest/evaluation.

Jean M. Elwing, MD Jean M. Elwing, MD
Professor of Medicine
Director, Pulmonary Hypertension Program
University of Cincinnati

Supported by independent educational grants from United Therapeutics, a public benefit company; Bayer U.S.; and Actelion Pharmaceuticals U.S., Inc., A Janssen Pharmaceutical Company of Johnson & Johnson

Launch Date: August 22, 2023
Release Date: August 22, 2023
Expiration Date: July 31, 2024

July 31, 2024
Mini Module